Geron Corp (GERN)

[big bambino]

Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes and IMbark Primary Analysis in Myelofibrosis to be Presented

Geron Corporation (Nasdaq: GERN) today announced that clinical data related to imetelstat, the Company’s first-in-class telomerase inhibitor, will be the subject of two oral presentations at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego, California from December 1-4, 2018. The abstracts, summarizing clinical data from Part 1 of IMerge in myelodysplastic syndromes and the IMbark primary analysis in myelofibrosis, were published today on the ASH website at www.hematology.org.

“We are pleased the abstracts for Part 1 of IMerge and IMbark were accepted for presentation at ASH,” said John A. Scarlett, M.D., Geron’s President and Chief Executive Officer. “We are looking forward to the oral presentations as they underscore imetelstat’s potential to address the unmet medical need in lower risk MDS and relapsed/refractory myelofibrosis.”